Crinetics Pharmaceuticals/$CRNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Ticker
$CRNX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
437
ISIN
US22663K1079
Website
CRNX Metrics
BasicAdvanced
$3B
-
-$3.82
0.28
-
Price and volume
Market cap
$3B
Beta
0.28
52-week high
$59.95
52-week low
$24.10
Average daily volume
729K
Financial strength
Current ratio
22.527
Quick ratio
22.359
Long term debt to equity
3.504
Total debt to equity
4.053
Profitability
EBITDA (TTM)
-373.494
Gross margin (TTM)
-34,512.50%
Net profit margin (TTM)
-43,191.05%
Operating margin (TTM)
-49,569.74%
Management effectiveness
Return on assets (TTM)
-20.13%
Return on equity (TTM)
-30.84%
Valuation
Price to revenue (TTM)
3,619.597
Price to book
2.39
Price to tangible book (TTM)
2.39
Price to free cash flow (TTM)
-10.368
Free cash flow yield (TTM)
-9.65%
Free cash flow per share (TTM)
-308.56%
Growth
Revenue change (TTM)
-61.50%
Earnings per share change (TTM)
1.41%
3-year revenue growth (CAGR)
-43.48%
3-year earnings per share growth (CAGR)
10.38%
What the Analysts think about CRNX
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
Bulls say / Bears say
Crinetics Pharmaceuticals' lead investigational compound, paltusotine, achieved positive topline results in the Phase 3 PATHFNDR-1 study for acromegaly, supporting its potential as a maintenance treatment. (crinetics.com)
The company reported profoundly positive initial results for atumelnant in treating congenital adrenal hyperplasia and Cushing’s disease, with additional data expected later in 2024. (crinetics.com)
Crinetics announced a $350 million private placement financing, expected to extend its cash runway into 2028, providing substantial resources for ongoing research and development. (crinetics.com)
The departure of Chief Commercial Officer James Hassard in October 2024 may lead to transitional challenges in the company's commercial strategy. (investing.com)
Crinetics plans a $400 million stock offering, which could dilute existing shareholders' equity and potentially impact stock value. (investing.com)
Insider selling activity, including the sale of 15,000 shares by Chief Medical and Development Officer Dana Pizzuti, might signal concerns about the company's future prospects. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CRNX Financial Performance
Revenues and expenses
CRNX Earnings Performance
Company profitability
CRNX News
AllArticlesVideos
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewsWire·6 hours ago
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·22 hours ago
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $3B as of July 11, 2025.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of July 11, 2025.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.